中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2013年
25期
339-340
,共2页
张志明%李扬%吕俊明%张信强
張誌明%李颺%呂俊明%張信彊
장지명%리양%려준명%장신강
晚期非小细胞肺癌%三维适形放疗%临床疗效
晚期非小細胞肺癌%三維適形放療%臨床療效
만기비소세포폐암%삼유괄형방료%림상료효
advanced non small cell lung cancer%three-dimensional conformal radiotherapy%clinical effect
目的探讨三维适形放疗治疗晚期非小细胞肺癌的临床疗效。方法将我院2010年1月至2012年6月间收治的92例晚期非小细胞肺癌患者随机分为常规放射治疗组(对照组)和三维适形放射治疗组(观察组),每组各46例,观察两组患者的近期疗效及毒副反应。结果观察组患者的临床疗效总有效率为76.1%,显著高于对照组患者的54.3%,组间差异有统计学意义(P<0.05)。观察组患者治疗后毒副反应发生率为28.3%,显著低于对照组患者的63.0%,组间差异有统计学意义(P<0.05)。结论采用三维适形放疗治疗晚期非小细胞肺癌临床疗效好,毒副反应发生率低,值得临床进一步推广使用。
目的探討三維適形放療治療晚期非小細胞肺癌的臨床療效。方法將我院2010年1月至2012年6月間收治的92例晚期非小細胞肺癌患者隨機分為常規放射治療組(對照組)和三維適形放射治療組(觀察組),每組各46例,觀察兩組患者的近期療效及毒副反應。結果觀察組患者的臨床療效總有效率為76.1%,顯著高于對照組患者的54.3%,組間差異有統計學意義(P<0.05)。觀察組患者治療後毒副反應髮生率為28.3%,顯著低于對照組患者的63.0%,組間差異有統計學意義(P<0.05)。結論採用三維適形放療治療晚期非小細胞肺癌臨床療效好,毒副反應髮生率低,值得臨床進一步推廣使用。
목적탐토삼유괄형방료치료만기비소세포폐암적림상료효。방법장아원2010년1월지2012년6월간수치적92례만기비소세포폐암환자수궤분위상규방사치료조(대조조)화삼유괄형방사치료조(관찰조),매조각46례,관찰량조환자적근기료효급독부반응。결과관찰조환자적림상료효총유효솔위76.1%,현저고우대조조환자적54.3%,조간차이유통계학의의(P<0.05)。관찰조환자치료후독부반응발생솔위28.3%,현저저우대조조환자적63.0%,조간차이유통계학의의(P<0.05)。결론채용삼유괄형방료치료만기비소세포폐암림상료효호,독부반응발생솔저,치득림상진일보추엄사용。
Objective To investigate the clinical effect of three dimensional conformal radiotherapy in treatment of advanced non-small cell lung cancer. Methods 92 cases of advanced non-small cell lung cancer in our hospital from 2010 January to 2012 June were randomly divided into routine therapy group (control group) and three-dimensional conformal radiation therapy group (observation group), 46 cases in each group, observed the clinical effect and toxicity of patients in two groups. Results The total effective rate of patients in observation group was 76.1%, signiifcantly higher than that in control group (54.3%), there was signiifcant difference between two groups (P<0.05). Patients in the observation group, adverse reaction rate was 28.3%, signiifcantly lower than that in control group(63%), there was signiifcant difference between two groups (P<0.05). Conclusion Taking three-dimensional conformal radiotherapy for advanced non-small cell lung cancer has good clinical effect, and adverse reaction rate is low, it is worthy of further clinical application.